Niraj Shah, MD
Internal Medicine · Joliet, ILNPI 1215248067
Payments from drug & device makers
Across 398 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Nestle Healthcare Nutrition Inc.$701
- AstraZeneca$626
- Johnson & Johnson$599
- Pfizer$565
- Novo Nordisk$336
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,188100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,187 |
| Nestle Healthcare Nutrition Inc. | 56 | $701 |
| AstraZeneca | 41 | $626 |
| Johnson & Johnson | 39 | $599 |
| Pfizer | 32 | $565 |
| Novo Nordisk | 18 | $336 |
| GSK | 17 | $287 |
| Novartis | 18 | $281 |
| Gilead | 14 | $234 |
| Amgen(2 entities) | 13 | $208 |
| Merck | 13 | $199 |
| Boehringer Ingelheim | 8 | $143 |
| Medtronic(2 entities) | 4 | $111 |
| Bayer | 6 | $88 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Lilly USA, LLC | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Echosens North America, Inc. | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Hologic Sales And Service, LLC | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Biogen | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$6,194 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $124,539 |
| MounjaroTirzepatide | 36 | $73,989 |
| JardianceEmpagliflozin | 39 | $71,748 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $64,095 |
| JanuviaSitagliptin Phosphate | 34 | $54,991 |
| TrulicityDulaglutide | 26 | $44,341 |
| EliquisApixaban | 54 | $41,871 |
| FarxigaDapagliflozin Propanediol | 25 | $35,751 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $34,391 |
| XareltoRivaroxaban | 29 | $32,218 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $31,514 |
| VraylarCariprazine Hcl | 14 | $23,202 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $19,898 |
| LinzessLinaclotide | 23 | $19,868 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $15,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $336 | $124,53987 claims |
| Lilly USA, LLCMounjaro, Trulicity | $62 | $118,33062 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $143 | $101,37875 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $287 | $70,43464 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $86 | $64,09558 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $626 | $61,80958 claims |
| MerckJanuvia | $199 | $54,99134 claims |
| AbbVieVraylar, Linzess | $1,187 | $43,07037 claims |
| PfizerEliquis | $565 | $41,87154 claims |
| Johnson & JohnsonXarelto | $599 | $32,21829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Joliet
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.